Claims for Patent: 6,492,512

Summary for Patent: 6,492,512

Title:	Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression
Abstract:	An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of lung cancer.
Inventor(s):	Thompson; James D. (Boulder, CO), Draper; Kenneth G. (Boulder, CO)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	07/936,532
Patent Claims:	1. An enzymatic RNA molecule which specifically cleaves mRNA produced from the human gene L-myc. 2. The enzymatic RNA molecule of claim 1 which specifically cleaves mRNA sequence comprising any of SEQ. ID. NOS. 1-17, wherein said enzymatic RNA molecule is in a hammerhead motif. 3. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule is in a hammerhead motif. 4. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule is in a hairpin, hepatitis Delta virus, group I intron, or RNAseP RNA motif. 5. The enzymatic RNA of any of any of claims 1, 3, 4, or 5, wherein said enzymatic RNA comprises between 5 and 23 bases complementary to said mRNA. 6. The enzymatic RNA of claim 5, wherein said enzymatic RNA comprises between 10 and 18 bases complementary to said mRNA. 7. An isolated mammalian cell comprising the enzymatic RNA molecule of any of claims 1, 3, 4, or 5. 8. The mammalian cell of claim 7, wherein said mammalian cell is a human cell. 9. An expression vector comprising nucleic acid sequence encoding the enzymatic RNA molecule of any of claims 1, 3, 4, or 5, in a manner which allow expression of that enzymatic RNA molecule. 10. An isolated mammalian cell comprising the expression vector of claim 9. 11. The mammalian cell of claim 10, wherein said mammalian cell is a human cell. 12. The enzymatic RNA molecule of any of claims 1, 3, 4, or 5, wherein said RNA comprises at least one sugar modification. 13. The enzymatic nucleic acid of any of claims 1, 3, 4, or 5, wherein said RNA comprises at least one base modification. 14. The enzymatic nucleic acid of any of claims 1, 3, 4, or 5, wherein said RNA comprises at least one phosphate modification. 15. The enzymatic nucleic acid of claim 14, wherein said phosphate modification is a phosphorothioate.

Details for Patent 6,492,512

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26